Global T-cell Lymphoma Market

Report ID : 1312 | Published : 2022-07-12 | Pages: 188 | Format: PDF/EXCEL

The Global T-cell Lymphoma market size was accounted at USD 1.44 Bn in 2021; It is projected to grow at a compound annual growth rate (CAGR) of 8.40% from 2022 to 2030. T-cell lymphoma is a rare type of cancerous lymphoma that begins in white blood cells (T cells). Lymphoma arises from the uncontrolled growth of mature T cells and can become cancerous. It can cause skin redness, scaly round patches on the skin, and skin tumors.

Several factors driving the growth of the T-cell Lymphoma Market include the rising lymphoma cancer cases,  increasing technological advances in therapy techniques, increasing T-cell lymphoma-specific therapies, and increasing autoimmune disorders. Moreover, spreading awareness regarding the benefits of T-cell lymphoma therapeutics, surging demand for cost-efficient cancer treatments and boosting government funding for the R&D of innovative cancer therapies are further expected to deliver considerable market growth during the forecast period. According to Leukemia & Lymphoma Society 2020, around 85,720 new lymphoma cases were diagnosed in the United States in 2020. Additionally, the newly reported lymphoma cases include 8,480 cases of Hodgkin (HL) and 77,240 cases of Non-Hodgkin (NHL) Lymphoma, thereby upsurging the demand for this market.

However, the high cost of T-cell Lymphoma therapies, complicated production methods, and side effects of these therapies may restrict the market growth in the upcoming years. 

The T-cell Lymphoma Market is classified based on lymphoma type, therapy, and region. By lymphoma type, the market is segmented into peripheral T-cell lymphoma and T-cell lymphoblastic lymphoma. Peripheral T-cell lymphoma is further divided into cutaneous T-cell lymphoma, anaplastic large cell lymphoma, angio-immuno-blastic T-cell lymphoma, and others (intestinal T-cell lymphoma, follicular T-cell lymphoma). By therapy, the market is grouped into radiotherapy, chemotherapy, immunotherapy, stem cell transplantation, and others (antiviral treatment, etc.). The chemotherapy segment is expected to lead this market during the forecast years due to its increasing use for cancer treatments. Regionally, the market is segregated across North America, Europe, Asia-Pacific, Latin America, and the Middle East & Africa. North America is anticipated to dominate the T-cell lymphoma market over the forecast period (2020-2030), owing to the increasing R&D expenditure and rising incidences of lymphoma in this region.

Few key players operating in the T-cell lymphoma market are 4SC AG, Acrotech Biopharma, Affimed, Bausch Health Companies Inc., Biocryst Pharmaceuticals Inc., Bristol-Myers Squibb Company, Chipscreen Biosciences, Citius Pharma, CSPC, CStone Pharmaceuticals, Daiichi-Sankyo, Dizal Pharma, Eisai, Elorac, F. Hoffmann-La Roche Ltd, Genmab A/S, Genor Biopharma, GlaxoSmithKline plc., Innate Pharma, Johnson and Johnson Private Limited, Kyowa Kirin Co., Ltd., Merck and Co. Inc., Novartis AG, Pfizer, Roche, Seagen Inc., Secura Bio, Shanghai Junshi Bio, SHIONOGI & Co., Ltd., Solasia, Spectrum Pharmaceuticals Inc., Takeda, Viracta, and Other Prominent Players.

Chapter 1. Methodology and Scope

1.1. Research Methodology

1.2. Research Scope & Assumptions

Chapter 2. Executive Summary

Chapter 3. Global T-cell Lymphoma Market Snapshot

Chapter 4. Global T-cell Lymphoma Market Variables, Trends & Scope

4.1. Market Segmentation & Scope

4.2. Drivers

4.3. Challenges

4.4. Trends

4.5. Investment and Funding Analysis

4.6. Industry Analysis – Porter’s Five Forces Analysis

4.7. Competitive Landscape & Market Share Analysis

4.8. Impact of Covid-19 Analysis

Chapter 5. Market Segmentation 1: By Lymphoma Type Estimates & Trend Analysis

5.1. By Lymphoma Type & Market Share, 2020 & 2030

5.2. Market Size (Value US$ Mn) & Forecasts and Trend Analyses, 2020 to 2030 for the following By Lymphoma Type:

5.2.1. Peripheral T-cell Lymphoma

5.2.1.1. Cutaneous T-cell Lymphoma

5.2.1.2. Anaplastic Large Cell Lymphoma

5.2.1.3. Angio-immuno-blastic T-cell Lymphoma

5.2.1.4. Others

5.2.1.4.1. Intestinal T-cell Lymphoma

5.2.1.4.2. Follicular T-cell lymphoma

5.2.2. T-cell Lymphoblastic Lymphoma

Chapter 6. Market Segmentation 2: By Therapy Estimates & Trend Analysis

6.1. By Therapy & Market Share, 2020& 2030

6.2. Market Size (Value US$ Mn) & Forecasts and Trend Analyses, 2020 to 2030 for the following By Therapy:

6.2.1. Radiotherapy

6.2.2. Chemotherapy

6.2.3. Immunotherapy

6.2.4. Stem Cell Transplantation

6.2.5. Others (Antiviral Therapy, etc.)

Chapter 7. T-cell Lymphoma Market Segmentation 3: Regional Estimates & Trend Analysis

7.1. North America

7.1.1. North America T-cell Lymphoma Market revenue (US$ Million) estimates and forecasts By Lymphoma Type, 2019-2030

7.1.2. North America T-cell Lymphoma Market revenue (US$ Million) estimates and forecasts By Therapy, 2019-2030

7.1.3. North America T-cell Lymphoma Market revenue (US$ Million) estimates and forecasts by country, 2019-2030

7.2. Europe

7.2.1. Europe T-cell Lymphoma Market revenue (US$ Million) By Lymphoma Type, 2019-2030

7.2.2. Europe T-cell Lymphoma Market revenue (US$ Million) By Therapy, 2019-2030

7.2.3. Europe T-cell Lymphoma Market revenue (US$ Million) by country, 2019-2030

7.3. Asia Pacific

7.3.1. Asia Pacific T-cell Lymphoma Market revenue (US$ Million) By Lymphoma Type, 2019-2030

7.3.2. Asia Pacific T-cell Lymphoma Market revenue (US$ Million) By Therapy, 2019-2030

7.3.3. Asia Pacific T-cell Lymphoma Market revenue (US$ Million) by country, 2019-2030

7.4. Latin America

7.4.1. Latin America T-cell Lymphoma Market revenue (US$ Million) By Lymphoma Type, 2019-2030

7.4.2. Latin America T-cell Lymphoma Market revenue (US$ Million) By Therapy, 2019-2030

7.4.3. Latin America T-cell Lymphoma Market revenue (US$ Million) by country, 2019-2030

7.5. Middle East & Africa

7.5.1. Middle East & Africa T-cell Lymphoma Market revenue (US$ Million) By Lymphoma Type, 2019-2030

7.5.2. Middle East & Africa T-cell Lymphoma Market revenue (US$ Million) By Therapy, 2019-2030

7.5.3. Middle East & Africa T-cell Lymphoma Market revenue (US$ Million) by country, 2019-2030

Chapter 8. Competitive Landscape

8.1. Major Mergers and Acquisitions/Strategic Alliances

8.2. Company Profiles

8.2.1. 4SC AG

8.2.2. Acrotech Biopharma

8.2.3. Affimed

8.2.4. Bausch Health Companies Inc.

8.2.5. Biocryst Pharmaceuticals Inc.

8.2.6. Bristol-Myers Squibb Company

8.2.7. Chipscreen Biosciences

8.2.8. Citius Pharma

8.2.9. CSPC

8.2.10. CStone Pharmaceuticals

8.2.11. Daiichi-Sankyo

8.2.12. Dizal Pharma

8.2.13. Eisai

8.2.14. Elorac

8.2.15. F. Hoffmann-La Roche Ltd

8.2.16. Genmab A/S

8.2.17. Genor Biopharma

8.2.18. GlaxoSmithKline plc.

8.2.19. Innate Pharma

8.2.20. Johnson and Johnson Private Limited

8.2.21. Kyowa Kirin Co., Ltd.

8.2.22. Merck and Co. Inc.

8.2.23. Novartis AG

8.2.24. Pfizer

8.2.25. Roche

8.2.26. Seagen Inc.

8.2.27. Secura Bio

8.2.28. Shanghai Junshi Bio

8.2.29. SHIONOGI & Co., Ltd.

8.2.30. Solasia

8.2.31. Spectrum Pharmaceuticals Inc.

8.2.32. Takeda

8.2.33. Viracta

8.2.34. Other Prominent Players

Market Segmentation

Global T-cell Lymphoma Market, by Lymphoma Type, 2020-2030 (Valu US$ Mn)

  • Peripheral T-cell Lymphoma
    • Cutaneous T-cell Lymphoma
    •  Anaplastic Large Cell Lymphoma
    •  Angio-immuno-blastic T-cell Lymphoma
    •  Others
      • Intestinal T-cell Lymphoma
      •  Follicular T-cell lymphoma
  • T-cell Lymphoblastic Lymphoma

Global T-cell Lymphoma Market, by Therapy, 2020-2030 (Value US$ Mn)

  • Radiotherapy
  • Chemotherapy
  • Immunotherapy
  • Stem Cell Transplantation
  • Others (Antiviral Therapy, etc.)

Global T-cell Lymphoma Market, by Region, 2020-2030 (Value US$ Mn)

  • North America
  • Europe
  • Asia Pacific
  • Latin America
  • Middle East & Africa

North America T-cell Lymphoma Market, by Country, 2020-2030 (Value US$ Mn)

  • U.S.
  • Canada

Europe T-cell Lymphoma Market, by Country, 2020-2030 (Value US$ Mn)

  • Germany
  • France
  • Italy
  • Spain
  • Russia
  • Rest of Europe

Asia Pacific T-cell Lymphoma Market, by Country, 2020-2030 (Value US$ Mn)

  • India
  • China
  • Japan
  • South Korea
  • Australia & New Zealand

Latin America T-cell Lymphoma Market, by Country, 2020-2030 (Value US$ Mn)

  • Brazil
  • Mexico
  • Rest of Latin America

Middle East & Africa T-cell Lymphoma Market, by Country, 2020-2030 (Value US$ Mn)

  • GCC Countries
  • South Africa
  • Rest of Middle East & Africa

 

InsightAce Analytic follows a standard and comprehensive market research methodology focused on offering the most accurate and precise market insights. The methods followed for all our market research studies include three significant steps – primary research, secondary research, and data modeling and analysis - to derive the current market size and forecast it over the forecast period. In this study, these three steps were used iteratively to generate valid data points (minimum deviation), which were cross-validated through multiple approaches mentioned below in the data modeling section.

Through secondary research methods, information on the market under study, its peer, and the parent market was collected. This information was then entered into data models. The resulted data points and insights were then validated by primary participants.

Based on additional insights from these primary participants, more directional efforts were put into doing secondary research and optimize data models. This process was repeated till all data models used in the study produced similar results (with minimum deviation). This way, this iterative process was able to generate the most accurate market numbers and qualitative insights.

Secondary research

The secondary research sources that are typically mentioned to include, but are not limited to:

  • Company websites, financial reports, annual reports, investor presentations, broker reports, and SEC filings.
  • External and internal proprietary databases, regulatory databases, and relevant patent analysis
  • Statistical databases, National government documents, and market reports
  • Press releases, news articles, and webcasts specific to the companies operating in the market

The paid sources for secondary research like Factiva, OneSource, Hoovers, and Statista

Primary Research:

Primary research involves telephonic interviews, e-mail interactions, as well as face-to-face interviews for each market, category, segment, and subsegment across geographies

The contributors who typically take part in such a course include, but are not limited to: 

  • Industry participants: CEOs, CBO, CMO, VPs, marketing/ type managers, corporate strategy managers, and national sales managers, technical personnel, purchasing managers, resellers, and distributors.
  • Outside experts: Valuation experts, Investment bankers, research analysts specializing in specific markets
  • Key opinion leaders (KOLs) specializing in unique areas corresponding to various industry verticals
  • End-users: Vary mainly depending upon the market

Data Modeling and Analysis:

In the iterative process (mentioned above), data models received inputs from primary as well as secondary sources. But analysts working on these models were the key. They used their extensive knowledge and experience about industry and topic to make changes and fine-tuning these models as per the product/service under study.

The standard data models used while studying this market were the top-down and bottom-up approaches and the company shares analysis model. However, other methods were also used along with these – which were specific to the industry and product/service under study.

To know more about the research methodology used for this study, kindly contact us/click here.

Need Complete Report ?

Frequently Asked Questions

Who are the Key Players in the Global T-cell Lymphoma Market?

T-cell Lymphoma Market is worth US$ 1.44 Billion in 2021

CAGR of 8.40% during the forecast period of 2022-2030.

Our Clients